Biotechnology

NeuExcell Therapeutics Announces Successful Dosing of First Patient by NeuroD1 Gene Therapy

SUZHOU, China, March 22, 2024 /PRNewswire/ -- NeuExcell Therapeutics, a leading biotechnology company focused onin vivo neural regenerative therapies, announces the successful dosing of the first patient with the first-in-class NeuroD1 gene therapy product NXL-004. This milestone represents si...

2024-03-22 08:00 3302

Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved

SHANGHAI, March 21, 2024 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 annual results. During the reporting period, Henlius' revenue reached about RMB5.3949 billion, representing an increase of 67.8% YoY, and recorded a net profit ofRMB546.0 million. This is the first time for Henlius to a...

2024-03-21 19:47 5275

SK bioscience Exports Influenza Vaccine to Thailand, Entering Southern Hemisphere Market

* Company exported 440,000 doses to Thailand, marking its entry into the Southeast Asian market and the Southern Hemisphere market. * Company has obtained marketing authorizations in 12 countries, with additional approvals underway in 10 countries to expand its market worldwide. BANGKOK and S...

2024-03-21 13:24 4229

TreeFrog's Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)

- TreeFrog Therapeutics demonstrates fast, sustained, full motor recovery in preclinical models for Parkinson's Disease cell therapy program using C-Stem™ proprietary technology[1] -   BORDEAUX, France, March 21, 2024 /PRNewswire/ -- TreeFrog Therapeutics, a cell therapy development company with...

2024-03-21 07:30 2983

Jiangsu Recbio Technology Co., Ltd. announced 2023 annual results report and latest progress

TAIZHOU, China, March 21, 2024 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announced its latest progress and annual results for 2023. The company always adhered to the mission of " Protect Human Health With Best-In-Class Vaccines", and achieved the following milestones and progre...

2024-03-21 00:22 5146

Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia

SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in he...

2024-03-20 20:30 3514

Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study

* ATN-031 (also known as ATG-031), is the first anti-CD24 antibody to advance to the clinic in oncology inthe United States * The Phase I PERFORM trial, ongoing at four major U.S. cancer centers, is evaluating the safety and preliminary efficacy of ATN-031 in patients with advanced solid tumor...

2024-03-20 20:30 3215

Innovent Announces 2023 Annual Results and Business Updates

A transformative year of strong performance and material innovation progress ROCKVILLE, M.D. and SUZHOU, China, March 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality med...

2024-03-20 19:44 5530

Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies

Proceeds to Support Advancement of Engrail's Pipeline for Neuropsychiatric and Neurodevelopmental Disorders  SAN DIEGO, March 20, 2024 /PRNewswire/ -- Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to impro...

2024-03-20 11:00 3113

Antengene Publishes Preclinical Paper on PD-L1/4-1BB Bispecific Antibody ATG-101 in Renowned Oncology Journal Cancer Research

SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in he...

2024-03-20 08:30 2805

Samsung Medison and Bracco Imaging Forge Path with New Diagnostic Ultrasound Technology Agreement at ECR 2024

The collaboration aims to improve ultrasound contrast agent utilization and image resolution, streamline workflow, and enhance clinical benefits for users and patients. MILAN, March 19, 2024 /PRNewswire/ -- Samsung Medison (CEO, Mr. Yongkwan Kim) and Bracco Imaging (CEO, Dr. Fulvio Renoldi Bracc...

2024-03-19 18:00 3679

LifeSpan Vision Ventures Invests in SENISCA

NORWALK, Conn., March 19, 2024 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm specializing in longevity biotech investments, today announced an investment in SENISCA, an RNA therapeutics spinout from the University of Exeter. The company has developed proprietary technology that har...

2024-03-19 17:00 2445

Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)

ROCKVILLIE, Md. and SUZHOU, China, March 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major d...

2024-03-19 08:00 4234

EDAN and GH Labs Collaborate to Develop AI-Enabled Ultrasound Devices

BELLEVUE, Wash., March 18, 2024 /PRNewswire/ -- Edan Instruments, Inc. (300206.SZ), a leading global provider of medical and healthcare solutions, announces a collaboration with Global Health Labs, Inc. (GH Labs) to co-develop AI-enabled ultrasound devices. The ...

2024-03-18 19:45 5567

Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer

SHANGHAI, March 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, today announced that the company has strengthened i...

2024-03-18 09:00 4262

SOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish Results from Multiyear Collaboration

New Multimodal Algorithm Highlights Predictive Benefit Of Artificial Intelligence (AI) for Cancer Research BOSTON and ROLLE, Switzerland, March 15, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, and the French Kidney Can...

2024-03-15 18:00 3475

Novartis expands its biopharmaceutical manufacturing site in Singapore

* Invests US$256 million to expand biopharmaceutical manufacturing facility in Singapore, addressing the soaring demand in the Asian market  * Set to generate 100 high skilled employment opportunities in Singapore's life science industry  SINGAPORE, March 15, 2024 /PRNewswire/ -- Novartis today...

2024-03-15 14:55 4435

Seegene and Springer Nature Announce Awardees for the Open Innovation Program

* 26 submissions selected from a total of 281 applications from 47 countries to diagnose infectious and vector-borne diseases * Awardees representing 12 countries in Europe, the Americas, Asia and Africa , will receive research grants of up toUSD 600,000 per project * As part of the Seegene's...

2024-03-15 13:41 4064

CStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer

* Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. * This marks the 13th NDA approval obtained by CStone and sugemalimab's fifth indication approved inChina, following stage III and IV no...

2024-03-15 12:10 4652

Angel Yeast Hosts Community Welfare Activity in Egypt, Promoting Green Development and Cultural Exchanges

SHANGHAI, March 15, 2024 /PRNewswire/ -- Angel Yeast , (SH600298), the world's leading yeast manufacturer, recently hosted a community Welfare Activity on sustainable and green development for the students at a school near its factory inEgypt and gave gifts to the stude...

2024-03-15 09:04 5073
1 ... 72737475767778 ... 185